IGF-1 LR3

This foundational study produced and characterized Long-[Arg3]-IGF-I (LR3), which combines a 13-residue N-terminal extension with a Glu3-to-Arg3 substitution. In cell lines that secrete IGF binding proteins (e.g., L6 myoblasts), LR3-IGF-I was substantially more potent than native IGF-I at stimulating protein synthesis, whereas in cells lacking detectable IGFBP secretion it was actually less potent, demonstrating that the enhanced biological potency derives from reduced IGFBP binding rather than increased affinity for the type 1 IGF receptor. The work established the mechanistic rationale that LR3's activity depends on escaping IGFBP sequestration to raise the free, receptor-available fraction.

Researchers engineered the modified growth factor now called IGF-1 LR3 and tested it in cell cultures. It worked more strongly than ordinary IGF-1, but only in cells that release the carrier proteins that normally trap IGF-1; in cells without those carriers it was weaker. This showed that LR3's extra strength comes from avoiding being bound up by carrier proteins, not from binding the growth-factor receptor more tightly. The study was done entirely in cell culture, not in people.

Continuous infusion of Long-R3-IGF-I in guinea pigs stimulated growth of specific organs (notably the spleen, kidney and gut) while paradoxically lowering circulating endogenous IGF-I, IGF-II and IGF binding protein concentrations, consistent with negative feedback suppression of the somatotropic axis. Because LR3 binds IGFBPs poorly, it distributes and acts differently from native IGF-I, driving tissue growth even as it depresses the endogenous IGF system. The findings illustrate both the anabolic organ-specific effects and the systemic feedback consequences of a poorly-IGFBP-bound analog in a live animal model.

In guinea pigs, giving IGF-1 LR3 continuously made certain organs grow larger, but at the same time it lowered the animals' own natural IGF-1 and its carrier proteins in the blood. This suggests the body senses the extra activity and dials back its own production as a feedback response. It is an animal study that highlights both growth effects and the potential to disrupt the body's normal growth-factor balance.

In in vitro-produced bovine embryos, native IGF-I and Long-R3-IGF-I exerted distinct effects on developmental competence and on mRNA abundance for IGF binding proteins and the type 1 IGF receptor, indicating that the two ligands are not interchangeable despite acting through the same receptor. The differences were attributed to LR3's reduced IGFBP binding, which alters local ligand availability and downstream transcriptional regulation of the IGF axis in developing embryos.

When added to cattle embryos grown in the lab, ordinary IGF-1 and IGF-1 LR3 had different effects on how the embryos developed and on which growth-related genes were switched on. This means the modified version does not simply mimic natural IGF-1 even though they use the same receptor. The work is from reproductive and agricultural research, not human medicine.